You are here: Industry Insights > Dj

News List

How Africa vaccine production would boost global adjuvants market SHEM OIRERE
September 15, 2021
The drive to expand vaccine manufacturing in Africa is gaining momentum with several new partnership agreements including technology transfer for the production of both malaria and COVID-19 vaccine...
Model ADJG120 Ampoule Automatic Inspection Machine PharmaSources.com
December 27, 2017
ADJG120 ampoule automatic detection machine introduced
Merck’s Keytruda obtains EC approval as adjuvant therapy for kidney cancer Pharmaceutical-Technology
January 28, 2022
In a Phase III trial, Keytruda lowered the disease recurrence or mortality risk by 32% versus placebo.
Avanti & Croda-Denmark: Advancing Vaccine Adjuvant Research CPhIonline
January 24, 2022
In 2020, researchers at Verndari, Inc. investigated a novel microarray skin patch vaccine incorporating subunit glycoprotein antigens and liposomal adjuvants into a trehalose co-formulation.
Asieris Announces the World's First Patient Dose Administered in Combination of Asieris'APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients prnasia
January 04, 2022
Asieris Pharmaceuticals (Asieris), a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors, today announced that the world's first patient dose...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® as Adjuvant Therapy for Renal Cell Carcinoma AmericanPharmaceuticalReview
December 20, 2021
Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA...
NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma pharmatimes
December 17, 2021
The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund.
Medicago and GSK Announce Positive Phase 3 Efficacy and Safety Results for Adjuvanted Plant-Based COVID-19 Vaccine Candidate AmericanPharmaceuticalReview
December 09, 2021
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline announced positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago's plant-based COVID-19 vaccine candidate in...
FDA Approves Merck’s KEYTRUDA® as Adjuvant Treatment for Patients with Stage IIB or IIC Melanoma AmericanPharmaceuticalReview
December 07, 2021
Merck announced that the FDA has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.
Merck’s Keytruda obtains FDA approval as adjuvant therapy for melanoma patients Pharmaceutical-Business-Review
December 07, 2021
Merck’s anti-PD-1 therapy, Keytruda, has obtained approval from the US Food and Drug Administration (FDA) as an adjuvant therapy for stage IIB or IIC melanoma patients aged 12 years and above.